Quality of sexual life of women using the contraceptive vaginal ring in extended cycles: Preliminary report

REFERENCES

• Caruso S, Malandrino C, Cicero C, et al. Quality of sexual life of women on oral contraceptive continued-regimen: Pilot study. J Sex Med 2013;10:460–6.
   PubMed Web of Science ®Google Scholar
• Oddens BJ. Women's satisfaction with birth control: A population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condom, natural family planning, and sterilization among 1466 women. Contraception 1999;59:277–86.
   PubMed Web of Science ®Google Scholar
• Caruso S, Agnello C, Intelisano G, et al. Sexual behavior of women taking low-dose oral contraceptive containing 15 μg ethinylestradiol/60 μg gestodene. Contraception 2004;269:237–40.
   Google Scholar
• Shrader SP, Dickerson LM. Extended- and continuous-cycle oral contraceptives. Pharmacotherapy 2008;28: 1033–40.
   PubMed Web of Science ®Google Scholar
• Weisberg E. Contraceptive options for women in selected circumstances. Best Pract Res Clin Obstet Gynaecol 2010;24:593–604.
   PubMed Web of Science ®Google Scholar
• Brache V, Payan LJ, Faundes A. Current status of contraceptive vaginal rings. Contraception 2013;87: 264–72.
   PubMed Web of Science ®Google Scholar
• Bruni V, Pontello V, Luisi S, Petraglia F. An open- label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing. Eur J Obstet Gynecol Reprod Biol 2008;139: 65–71.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli A, et al. Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: A prospective randomized study. Contraception 2009; 80:34–9.
   PubMed Web of Science ®Google Scholar
• Wieder DR, Pattimakiel L. Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®). Int J Womens Health 2010;2:401–9.
   PubMedGoogle Scholar
• Roumen FJ, Mishell DR Jr. The contraceptive vaginal ring, NuvaRing®, a decade after its introduction. Eur J Contracept Reprod Health Care 2012;17:415–27.
   PubMed Web of Science ®Google Scholar
• Novák A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: An international study of user acceptability. Contraception 2003;67:187–94.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Smith V, Coffee A, et al. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: A randomized controlled trial. Obstet Gynecol 2008; 112:563–71.
   PubMed Web of Science ®Google Scholar
• Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: A randomized trial. Obstet Gynecol 2005;106:473–82.
   PubMed Web of Science ®Google Scholar
• Grodnitskaya EE, Grigoryan OR, Klinyshkova EV, et al. Effect on carbohydrate metabolism and analysis of acceptability (menstrual cycle control) of extended regimens of the vaginally inserted hormone-releasing system ‘NuvaRing’ as compared with the standard 21/7 regime in reproductive-age women with type 1 diabetes mellitus. Gynecol Endocrinol 2010;26:663–8.
   PubMed Web of Science ®Google Scholar
• Barreiros FA, Guazzelli CA, Barbosa R, et al. Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: Effects on lipid metabolism. Contraception 2011;84:155–9.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use, 4th edn. Geneva: World Health Organization 2009. Accessed 9 April 2014 from: http://whqlibdoc.who.int/publications/2010/9789241563888 _eng.pdf?ua = 1
   Google Scholar
• Caruso S, Agnello C, Malandrino C, et al. Do hormones influence women's sex? Sexual activity over the menstrual cycle. J Sex Med 2014;11:211–21.
   PubMed Web of Science ®Google Scholar
• Basson R, Leiblum S, Brotto L, et al. Revised definitions of women's sexual dysfunction. J Sex Med 2004;1: 40–8.
   PubMed Web of Science ®Google Scholar
• Ware JE, Kosinski M, Gandek B, et al. The factor structure of the SF-36 Health Survey in 10 countries: Results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 1998; 51:1159–65.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Albani F, Vaccaro P, et al. Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecol Endocrinol 2008;24:214–9.
   PubMed Web of Science ®Google Scholar
• Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31: 1–20.
   PubMed Web of Science ®Google Scholar
• Derogatis LR, Rosen R, Leiblum S, et al. The Female Sexual Distress Scale (FSDS): Initial validation of a standardized scale for assessment of sexually related personal in distress women. J Sex Marital Ther 2002;28: 317–30.
   PubMed Web of Science ®Google Scholar
• Glantz SA, ed. Primer of biostatistics. New York: McGraw-Hill Companies, Inc. 2005.
   Google Scholar
• Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304–11.
   PubMed Web of Science ®Google Scholar
• Burrows LJ, Basha M, Goldstein AT. The effects of hormonal contraceptives on female sexuality: A review. J Sex Med 2012;9:2213–23.
   PubMed Web of Science ®Google Scholar
• Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception – oral versus intravaginal – on the sexual life of women and their partners. Hum Reprod 2005;20:1100–6.
   PubMed Web of Science ®Google Scholar
• Caruso S, Iraci Sareri M, Agnello C, et al. Conventional vs. extended-cycle oral contraceptives on the quality of sexual life: Comparison between two regimens containing 3 mg drospirenone and 20 μg ethinyl estradiol. J Sex Med 2011;8:1478–85.
   PubMed Web of Science ®Google Scholar
• Caruso S, Agnello C, Intelisano G, et al. Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005;72:19–23.
   PubMed Web of Science ®Google Scholar
• Lete I, Cuesta MC, Marín JM, Guerra S. Vaginal health in contraceptive vaginal ring users – A review. Eur J Contracept Reprod Health Care 2013;18:234–41.
   PubMed Web of Science ®Google Scholar
• Smith NK, Jozkowski KN, Sanders SA. Hormonal contraception and female pain, orgasm and sexual pleasure. J Sex Med 2014;11:462–70.
   PubMed Web of Science ®Google Scholar
• Machadoa RB, de Melob NR, Maia H Jr. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: A randomized study. Contraception 2010;81:215–22.
   PubMed Web of Science ®Google Scholar
• Lin K, Barnhart K. The clinical rationale for menses- free contraception. J Womens Health (Larchmt) 2007;16: 1171–80.
   PubMed Web of Science ®Google Scholar